Answer FAQs About Insulin for Type 2 Diabetes

Insulin is in the spotlight...and you can help answer questions.

Medicare Part D now caps insulin co-pays at $35/month.   And manufacturers are rolling out their own co-pay caps...and lower prices.

Plus Rezvoglar (insulin glargine-aglr) will soon join Semglee as a lower-cost interchangeable biosimilar for Lantus.

Get concise, unbiased advice for effective drug therapy, plus CE/CME

Prescriber's Letter includes:

  • 12 issues every year, with brief articles about new meds and guidelines
  • 48+ CE courses, including the popular CE-in-the-Letter
  • Quick reference drug comparison charts
  • Access to the entire archive

Already a subscriber? Log in

Volume pricing available. Get a quote